Using xCELLigence as a evaluation tool, PD-1 inhibitor Nivolumab or Pembrolizumab alone has no significant effect in lung cancer PDO because of the loss of immune cells retained from the original tumor tissue. This evidence concerns the gene PDCD1 and lung cancer.